Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trial

Abstract

BackgroundThe prevalence and burden of atherosclerotic (AS) diseases are increasing during the last twenty years. Some studies show a close relationship between overweight and AS, but influence on AS diseases of different weight loss methods are still studying. The purpose of the research was to study the effectiveness of a weight loss program in AS patients in randomized controlled trial, and to develop a conception of evolution of AS.MethodsA randomized controlled prospective clinical trial including 97 people, from them 71 patients with various AS manifestations. Patients were divided in 2 subgroups for non-drug weight loss program, and conventional drug therapy. The weight loss program included calorie restriction with 100–150 kcal/day, fat-free vegetables, salt diet, and optimum physical activity. Statistical analysis was performed using SPSS for Windows version 17.0.ResultsThe weight loss subgroup lost ranging between 7-20 % from an initial weight (P = 0.016). Weight loss was achieved due to fatty mass reduction only (P = 0.005). Hemoglobin levels (P < 0.001), bone mineral density (P < 0.001), percentages of water (P = 0.006) and muscle masses (P = 0.0038) were increased in weight loss subgroup. Ejection fraction (P < 0.0001), systolic output (P < 0.0001) were increased in patients with coronary artery disease. The weight loss program led to a decrease in symptomatic drugs doses up to total abolition. A conception of AS was developed.ConclusionsThe weight loss program treated the AS diseases; improved laboratory and instrumental parameters, decreased symptomatic drugs doses. AS development is a logical way of ontogenetic ageing of body fat.Trial international registrationClinicalTrials.gov NCT01700075.Trial national registrationState registration is # 0109RK000079, code is O.0475 at the National Center for Scientific and Technical Information of the Republic of Kazakhstan.

Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases

“…Since obesity is a risk factor of CVDs, the direct potential effect of CR in the prevention of CVDs is attributed to body weight reduction. Another randomized controlled clinical trial indicated that weight loss due to CR significantly improves the cardiac ejection fraction and systolic output in CAD individuals ( Oshakbayev et al, 2015 ). In 47 obese subjects undergoing 12-week CR, body weight reduction along with visceral fat area alteration was observed, which was correlated with relieved arterial stiffness measured by a decrease in cardio-ankle vascular index (CAVI) ( Nagayama et al, 2013 ).…”

Overweight Effects on Metabolic Rate, Chronic Diseases, Time Perception, Aging, and Lifespan: a Systematic Review

“…Endogenous lipolysis provides the body with nutrients, vitamins, trace elements. [61,62] Endogenous lipolysis starts only after ending of carbohydrate store, after 4-5 days of restriction diet. [73] Having a single meal per workday (usually after workhours) could be one of the modes to prevent weight regain.…”

“…[73] Having a single meal per workday (usually after workhours) could be one of the modes to prevent weight regain. [62,74] Conclusions (1) Body mass and food intake are the main causes to maintain high MR. Overweight is a balance between body potential energy and nutrient reserve.…”

Use of reverse diet kit as a treatment to regress atheroma in a known CAD patient: A case report

“…Obesity leads to an increase in the metabolic burden of the body as there is requirement for additional thermoregulation, synthetic, trophic, immunological, antitoxic functions and excretion of metabolic products from the tissue [ 7 ].…”